Bladder Catheterization After Mini-PCNL

NCT ID: NCT04570787

Last Updated: 2021-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-01

Study Completion Date

2022-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

60 patients

Inclusion Criteria:

* age from 18 to 70 years
* Indications for mini-PCNL
* ASA score: 1-3
* Single percutaneous access to pyelocaliceal system
* Size of solitary calculus up to 2.5 cm

Exclusion Criteria:

* Active urinary tract infection
* Coagulopathy
* Clinically significant infravesical obstruction (Qmax less than 10 ml / s, PVR more than 50 ml)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

60 patients after PCNL will be recruited and randomized into 2 groups (30 vs 30):

* No Catheterization after mini-PCNL (study) - the bladder catheterization is not performed.
* Catheterization after mini-PCNL (control) - the bladder will be drained with the urethral catheter.

All patients will fill out the VASP in 2, 6, 12, 24 hours after mini-PCNL. Ultrasound examination of urinary bladder will be performed after mini-PCNL. All the AE will be registered.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urolithiasis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Urolithiasis PCNL Bladder catheterisation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No Catheterization

After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. Bladder catheterization is not performed.

Group Type ACTIVE_COMPARATOR

Urinary bladder catheterisation

Intervention Type PROCEDURE

Installation of Foley catheter into the urinary bladder

Catheterization

After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. The bladder is to be drained with the urethral catheter in all cases.

Group Type ACTIVE_COMPARATOR

Urinary bladder catheterisation

Intervention Type PROCEDURE

Installation of Foley catheter into the urinary bladder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Urinary bladder catheterisation

Installation of Foley catheter into the urinary bladder

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 70 years
* Indications for mini-PCNL
* ASA score: 1-3
* Single percutaneous access to pyelocaliceal system
* Size of solitary stone up to 2.5 cm

Exclusion Criteria

* Active urinary tract infection
* Coagulopathy
* Clinically significant infravesical obstruction (Qmax less than 10 ml / s, PVR more than 50 ml)
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Petersburg State Pavlov Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Pavlov Saint Petersburg University

Saint Petersburg, , Russia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dmitry S Gorelov

Role: CONTACT

Phone: +79217964892

Email: [email protected]

Vladimir M Obidniak

Role: CONTACT

Phone: +79218944746

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dmitriy Gorelov, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

04/20-н

Identifier Type: -

Identifier Source: org_study_id